authors have to clarify whether hs-cTnT was entered as raw continuous data or after log transformation. 6. Kaplan-Meier analyses (and curves) are correct but information on KM estimates in each of the hs-cTnT subgroups (for all outcomes) was not provided. Thus I advise the authors to make a table with numbers events (plus KM estimates) for each outcome and for each of the 4 hs-cTnT subgroups. Furthermore, all figures need numbers of subjects at risk for each of the subgroups. 7. Although, hs-cTnT showed an independent association with outcomes of interest, it was not tested whether hs-cTnT improves the discriminatory power of the models for each of the outcomes. Thus I advise the authors to calculate the C statistic of the models before and after inclusion of tropoinin, and compare them to find whether troponin improves the discriminatory power of the models as regards the prediction of the outcome of interest. Other tests such as IDI or NRI may also be used. 8. Data on hs-TnT change (delta hs-cTnT) over the follow-up was not reported. This should be done for each of the subgroups. There may be, however a reverse relationship in which events increased hs-cTnT and not vice versa (reverse causality). Did the authors account for this likelihood?
REVIEWER
Peder Myhre Akershus University Hospital and University of Oslo, Norway REVIEW RETURNED 24-Nov-2016
GENERAL COMMENTS
Wenkai Xiao et al have explored the prognostic value of cTnT levels in a large population-based study from Beijing, China. The study is carefully conducted and the statistical methods are applied in a satisfactory manner. Still, there are some shortcomings of the manuscript that reduce the clinical impact. Also, there is a need for improved phrasing and grammar, especially the introduction (i.e. the first sentence). I would suggest that a native English speaker reviews the manuscript before submitting the revised version.
Major:
1. The authors have explored cTnT in association to endpoints: MACE, coronary event, stroke and all-cause mortality. However, development of heart failure or heart failure worsening is not explored as an end point. I think this would be of great interest as the increased levels found in the general population most of all seems related to left ventricular remodelling (cardiac structure) and less related to atherosclerosis. This point should also be more clearly addressed in the discussion, although it is mentioned at the bottom of page 18. Moreover, ECG-recordings of the patients, especially with regards to left ventricular hypertrophy, would be of great interest. If this is not available it should be reported in "limitations". 2. The multivariate analysis used to adjust for confounders are done well. Still, I miss stratification of the results according to gender, as this has been shown to significantly influence the prognostic value of cTnT (Omland, Clin Chem 2015 
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 This is well-designed and reported study. I have only two suggestions: -First, the authors state that 181 participants were lost to follow up and excluded from the analysis. If baseline data on these subjects is available, this should be compared to the included patients and reported in the paper, to show if any significant differences existed. Response: I have compared the baseline data between the included and lost subjects, please see supplementary Table1. Compared with the included participants, the lost to follow up group were younger, had lower postprandial blood glucose, eGFR and NT-proBNP levels. Significant differences were not presented in other characteristics.
-Second, minor revision is needed to address some grammar/style issues. Response: Thanks for your professional suggestion. I have rewritten some sentences to improve the clarity and accuracy.
Reviewer: 2 1. Excellent written paper by Xiao et al. Response: Thanks. 2. The association between hs-cTnT and outcomes which includes mortality, CHD, HF and brain disease has been previously shown in multiple populations of healthy individuals (eg ARIC study publications) therefore commenting on how these results add to already existing publications would definitely strengthen the manuscript. Response: Just as what you mentioned, though the association between hs-cTnT and outcomes has been previously shown in multiple populations, our study extends the prognostic implications to Asians. I have commented the significance of this manuscript in discussion section. 3. hs-cTnT has been shown to be associated with subclinical brain disease in ARIC population (study not cited here) which shows that there may be other mechanisms that may explain the association between hs-cTnT and brain disease. Response: Just as what you mentioned, elevated plasma cTnT concentrations are associated with increased risk of cardioembolic and other nonlacunar ischemic but not with hemorrhagic strokes in ARIC population. While in our study hemorrhagic stroke accounts for more than one half of all strokes, I have analyzed the potential mechanisms of this difference. 4. Most manuscripts divided the cohort in quartiles of hs-cTnT. Commenting on why these cutoffs were chosen would improve the manuscript. Response: Thanks for your professional suggestion. Unlike other biomarkers, a substantial portion of hs-cTnT can not be detected in the general population, it was only detectable in 54.7% of our enrollment. what value are assigned in these undetectable population are controversial. Thus, for the categorical analyses, the 54.7% with undetectable levels were the reference group (group 1). With respect to elevated troponin (group 4), using the definition of ""elevated"" being, exceeds the 99th percentile value of a healthy reference population, for the hs-cTnT assay this threshold is specified by Roche to be 14ng/L. The remaining were split into two groups based on the median value of hs-cTnT in this range. To my knowledge, most manuscripts have taken this classification method. Reviewer: 3 1 The quality of English is less than optimal which is particularly evident in the introduction and discussion sections of the manuscript. Some terms also need correction; e.g., the term "coronary artery insufficiency" is not in use for almost 40 years; the log-rank test is not for the trend, as stated.
Response: I am very sorry for my imprecise English expression. I have rewritten and corrected some terms and sentences. Moreover, the revision has been edited by native English-speaking experts, I hope it could express my real intention more clearly and professionally. 2. The authors state to have performed a prospective population-based prospective observational study. However it remains unclear how subjects are recruited for the study. Does it mean that all adults in the district were included in the study? The authors give a list of exclusions but do not mention the inclusion criteria for the study. Please clarify this aspect and offer information on the age range of the subjects. An 11% rate of lost to follow-up is also of concern. Response: Thanks for your professional suggestion. I have supplied more details on recruitment of study population in the methods section. Please see the revision about the full details of the inclusion criteria and age range of the subjects 3. Definition of the study outcomes is incomplete. Specifically, definitions of nonfatal myocardial infarction and cardiac death are not provided. Mentioning of Cox analysis under the subheading Defintion of end points is inappropriate, Response: According to your advice, I have provided the definitions of nonfatal myocardial infarction and cardiac death in revision. Also the definition of survival time has been adjusted position. 4. Division of subjects into 4 groups is acceptable. However, groups 2 and 3 (subjects with hs-cTnT between 3 and 14 ng/L) may be divided based on median value of hs-cTnT in this range.
Response: My inappropriate expression (two equal-sized groups) leads to this ambiguity. In fact the remaining subjects were split into two groups based on the median value of hs-cTnT between 3 and 14 ng/L. I have corrected the expression in revision. 5. Hs-cTnT in population has a nonGaussian distribution. One solution is to use logarithmic scale (which was done by the authors). However, throughout the material all risk estimates (hazard ratios) should be calculated per unit of log hs-cTnT. In each of models, the authors have to clarify whether hs-cTnT was entered as raw continuous data or after log transformation.
Response: In this manuscript we modeled hs-cTnT as both a categorical and a continuous variable. For the analyses of hs-cTnT as a categorical variable, we divided participants into 4 categories: those with undetectable hs-cTnT were placed in the first category as the reference group. When hs-cTnT was regarded as a continuous variable, we analyzed the relationship between baseline and change in hs-cTnT levels with end points. In this analysis, the hs-cTnT levels were natural logarithm transformed and hazard ratios were calculated as per unit of log hs-cTnT increment. 6. Kaplan-Meier analyses (and curves) are correct but information on KM estimates in each of the hscTnT subgroups (for all outcomes) was not provided. Thus I advise the authors to make a table with numbers events (plus KM estimates) for each outcome and for each of the 4 hs-cTnT subgroups. Furthermore, all figures need numbers of subjects at risk for each of the subgroups. Response: The event numbers and event rate for each outcome across the 4 hs-cTnT subgroups had been provided in Table2, please see Table2. According to your advice, I have added the numbers of subjects at risk for each of the subgroups in Kaplan-Meier curves. For detailed information, see Figure1 in revision. 7. Although, hs-cTnT showed an independent association with outcomes of interest, it was not tested whether hs-cTnT improves the discriminatory power of the models for each of the outcomes. Thus I advise the authors to calculate the C statistic of the models before and after inclusion of tropoinin, and compare them to find whether troponin improves the discriminatory power of the models as regards the prediction of the outcome of interest. Other tests such as IDI or NRI may also be used. Response: Thanks for your professional suggestion. According to your advice, I have added the C statistic in revision (Table4). The area under the receiver operating characteristic curve summarized the diagnostic discrimination. The result shows that addition of troponin T levels to clinical variables led to significant increases in risk prediction with significant improvement of the c-statistic. 8. Data on hs-TnT change (delta hs-cTnT) over the follow-up was not reported. This should be done for each of the subgroups. There may be, however a reverse relationship in which events increased hs-cTnT and not vice versa (reverse causality). Did the authors account for this likelihood? Response: Thanks for your professional suggestion. Because in each of the subgroups, the hs-TnT may increase, decrease or unchanged, so we didn"t analyzed the kinetic changes of hs-TnT for each of the subgroups. In view of the markedly skewed distribution of hs-cTnT, changes in concentrations over time were calculated as the difference between the natural logarithm of the concentrations at follow-up and at baseline. Reviewer: 4 Wenkai Xiao et al have explored the prognostic value of cTnT levels in a large population based study from Beijing, China. The study is carefully conducted and the statistical methods are applied in a satisfactory manner. Still, there are some shortcomings of the manuscript that reduce the clinical impact. Also, there is a need for improved phrasing and grammar, especially the introduction (i.e. the first sentence). I would suggest that a native English speaker reviews the manuscript before submitting the revised version. Major: 1. The authors have explored cTnT in association to end-points: MACE, coronary event, stroke and all-cause mortality. However, development of heart failure or heart failure worsening is not explored as an end point. I think this would be of great interest as the increased levels found in the general population most of all seems related to left ventricular remodelling (cardiac structure) and less related to atherosclerosis. This point should also be more clearly addressed in the discussion, although it is mentioned at the bottom of page 18. Moreover, ECG-recordings of the patients, especially with regards to left ventricular hypertrophy, would be of great interest. If this is not available it should be reported in "limitations".
Response: Just as what you mentioned, heart failure is an important end point in the general population, the association between hs-cTnT and heart failure development has been previously shown in multiple populations. Unfortunately, due to ECG and echocardiogram were not available in our community survey, we failed to investigate the incidence of heart failure. I have discussed this aspect in "limitations".
2. The multivariate analysis used to adjust for confounders are done well. Still, I miss stratification of the results according to gender, as this has been shown to significantly influence the prognostic value of cTnT (Omland, Clin Chem 2015) . Also, there has been recent focus on the paradoxical impact of smoking on troponin levels (Lyngbakken, Circulation 2016). Your study is in support of this with a trend towards lower values in the highest quartiles of cTnT. This should be discussed. Also, the results should be discussed in relation to ethnicity. Response: Thanks for your professional suggestion. First, associations of cTnT level with all-cause mortality and major adverse cardiovascular event were consistent in stratification analysis defined by sex in our study. Second, our study population was restricted to Chinese Han origin inhabitant. Therefore, extrapolation of our results to other ethnic groups should be done with caution. I have discussed this in "limitations". 3. Finally, I would recommend the use of c-statistics in future studies like this to evaluate whether cTnT provides additional information to established models. Response: According to your advice, I have added the C statistic in revised version (Table4). The result shows that addition of troponin T levels to clinical variables led to significant increases in risk prediction with significant improvement of the c-statistic. Minor: 1. I miss the coefficient of variation (CV) for the different concentrations of cTnT. Please provide this if available.
Response: Sorry, the coefficient of variation for the different concentrations of cTnT is not available. Some data have reported that hs-cTnT by Roche have an interassay coefficient of variation of 8% at 10 pg/mL and 2.5% at 100 pg/mL. 2. Table 1 : I think it is more appropriate to provide p-values for Group 2-4 compared to Group 1 (reference) instead of using p-value for trend. Response: Thanks for your suggestion. We refer to some similar articles, they generally use the pvalue for trend in the comparison of clinical variables across cTnT categories. 3. Page 8, line 3 from the bottom: Please remove "serially" and use incrementally.
